EANO guideline on the diagnosis and treatment of vestibular schwannoma

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The level of evidence to provide treatment recommendations for vestibular schwannoma is low compared with other intracranial neoplasms. Therefore, the vestibular schwannoma task force of the European Association of Neuro-Oncology assessed the data available in the literature and composed a set of recommendations for health care professionals. The radiological diagnosis of vestibular schwannoma is made by magnetic resonance imaging. Histological verification of the diagnosis is not always required. Current treatment options include observation, surgical resection, fractionated radiotherapy, and radiosurgery. The choice of treatment depends on clinical presentation, tumor size, and expertise of the treating center. In small tumors, observation has to be weighed against radiosurgery, in large tumors surgical decompression is mandatory, potentially followed by fractionated radiotherapy or radiosurgery. Except for bevacizumab in neurofibromatosis type 2, there is no role for pharmacotherapy.

Related collections

Author and article information

Contributors

Michael Weller: (View ORCID Profile)

Journal

Title: Neuro-Oncology

Publisher: Oxford University Press (OUP)

ISSN (Print): 1522-8517

ISSN (Electronic): 1523-5866

Publication date Created: January 2020

Publication date Created: January 11 2020

Publication date Created: October 28 2019

Publication date Other: January 2020

Publication date (Print): January 11 2020

Publication date (Electronic): October 28 2019

Volume: 22

Issue: 1

Pages: 31-45

Affiliations

[1 ]Center of Neurosurgery, Department of General Neurosurgery, University of Cologne, Cologne, Germany

[2 ]Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland

[3 ]Department of Functional and Stereotactic Neurosurgery and Radiosurgery, Timone University Hospital, Marseille, France

[4 ]Department of Neurosurgery, Bergen University Hospital and Department of Clinical Medicine, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway

[5 ]Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany

[6 ]Manchester Centre for Genomic Medicine and NW Laboratory Genetics Hub, Manchester University Hospitals NHS Foundation Trust, Manchester, UK

[7 ]Department of Neurosurgery, Erasmus Hospital, Free University of Brussels, Brussels, Belgium

[8 ]Department of Neurosurgery, University Hospital San Carlos, Complutense University of Madrid, Madrid, Spain; University Hospital San Carlos, CyberKnife Centre, Genesiscare Madrid, Madrid, Spain

[9 ]Department of Neuroradiology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy

[10 ]Cambridge Skull Base Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

[11 ]Department of Otolaryngology, Unit of Otology, Auditory implants and Skull Base Surgery, Public Assistance–Paris Hospital, Pitié-Salpêtrière Group Hospital, Paris, France

[12 ]Unit of Radiotherapy, Neurological Institute Carlo Best, Milan, Italy

[13 ]Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany

[14 ]Department of Neurosurgery Ludwig-Maximilians University and DKTK partner site, University of Munich, Munich, Germany

Article

DOI: 10.1093/neuonc/noz153

PMC ID: 6954440

PubMed ID: 31504802

SO-VID: 4a8cef45-ad87-4198-a4ce-b2c407d27389

License:

https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

History

Data availability:

Comments

Comment on this article

scite_

Cited by 66

See all cited by

- Version 1
- Version 1